Sanofi | CIK:0001121404 | 3

  • Filed: 3/16/2018
  • Entity registrant name: Sanofi (CIK: 0001121404)
  • Generator: Donnelley Financial Solutions
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/0001193125-18-084834-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/sny-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001121404
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfAuditorsRemunerationExplanatory

    E/ Principal accountants’ fees and services

    PricewaterhouseCoopers Audit and Ernst & Young et Autres served as independent auditors of Sanofi for the year ended December 31, 2017 and for all other reporting periods presented. The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2017 and 2016.

     

         Ernst & Young      PricewaterhouseCoopers  
         2017     2016      2017      2016  

    ( million)

       Amount     %     Amount      %      Amount      %      Amount      %  
    Audit:                      
    Statutory audit of separate and consolidated financial statements(a)      16.4       73%       16.7        92%        16.8        98%        16.8        97%  
    Services other than statutory audit(b)      6.0       27%       1.4        8%        0.4        2%        0.6        3%  

    Audit-related services(c)

         4.9         0.6           0.4           0.4     

    Tax

         -         -           -           -     

    Other services

         1.1               0.8                 -                 0.2           
    Total      22.4       100%       18.1        100%        17.2        100%        17.4        100%  

     

      (a)

    Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst & Young: 7.6 million in 2017 and 7.0 million in 2016; PricewaterhouseCoopers 7.8 million in 2017 and 7.4 million in 2016.

     

      (b)

    Services other than statutory audit provided by Ernst & Young et Autres during 2017 comprised:

     

      -

    work on share capital transactions and securities issues submitted to the Annual General Meeting (in extraordinary business) for approval;

     

      -

    additional procedures to enable reports previously signed by the firm to be incorporated by reference; and

     

      -

    agreed-upon and audit procedures in connection with a divestment.

     

      Services

    other than statutory audit provided by PricewaterhouseCoopers Audit during 2017 comprised:

     

      -

    work on share capital transactions and securities issues submitted to the Annual General Meeting (in extraordinary business) for approval;

     

      -

    issuance of attestations;

     

      -

    additional procedures to enable reports previously signed by the firm to be incorporated by reference;

     

      -

    audit procedures in connection with an acquisition; and

     

      -

    benchmarking.

     

      (c)

    Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst & Young: 4.8 million in 2017 and 0.5 million in 2016; PricewaterhouseCoopers 0.3 million in 2017 and 0.1 million in 2016.

     

    Audit Committee pre-approval and procedures

    The Audit Committee of Sanofi has adopted a policy and established certain procedures for the approval of audit services and for the pre-approval of other services to be provided by the independent auditors. In 2017, the Audit Committee established a budget showing permitted audit-related and other services (i.e. services other than statutory audit) that can be provided by the independent auditors, and the related fees.